Urinary preparations
Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH)Generic
urofollitropin for injection, purified.Brands
Bravelle, U.S., (≤ 2 IU LH)
Metrodin, U.S. and Canada, (≤ 1 IU LH)
Fertinorm Hp, (Canada)Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH)Generic
urofollitropin for injection, (highly) purified.Dosage
typically 75 - 300, but as high as 600 IU / dayBrands
Fertinex (≤ 0.1 IU LH/1000 IU FSH)

Recombinant preparations
Follitropin alfaGeneric
Follitropin alfa injectionBrandsGonal-f
Cinnal-f
Fertilex
Ovaleap
BemfolaFollitropin betaGeneric
follitropin beta injectionBrands
Follistim AQ
PuregonFollitropin deltaGeneric
follitropin delta injectionBrands
RekovelleThe package insert for Gonal-f states that based on physio-chemical tests and bioassays that follitropin beta and follitropin alfa are indistinguishable. Two studies showed no difference. However, a more recent study showed there may be a slight clinical difference, with the alfa form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.The package insert for Puregon states that structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (hFSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural hFSH. However, these small differences do not affect the bioactivity compared to natural hFSH. Gonal-f was approved for medical use in the European Union in October 1995.Puregon was approved for medical use in the European Union in February 1996.Rekovelle was approved for medical use in the European Union in December 2016. Biosimilars
Ovaleap was approved for medical use in the European Union in September 2013.
Pexidartinib, sold under the brand  name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib blocks the activity of the colony-stimulating factor-1 receptor (CSF-1R). Common side effects are increased lactate dehydrogenase (proteins that helps produce energy in the body), increased aspartate aminotransferase (enzymes that are mostly in the liver but also in muscles), loss of hair color, increased alanine aminotransferase (enzymes that are primarily in the liver and kidney) and increased cholesterol. Additional side effects include neutropenia (low level of white blood cells that help the immune system defend against disease and infection), increased alkaline phosphatase (enzymes that are mostly in the cells of bone and the liver), decreased lymphocytes (white blood cells that help the immune system defend against disease and infection), eye edema (swelling around the eyes), decreased hemoglobin (protein in red blood cells that carry oxygen), rash, dysgeusia (altered sense of taste) and decreased phosphate (electrolytes that help with energy). The US prescribing information for pexidartinib includes a boxed warning about the risk of serious and potentially fatal liver injury.In August 2019, it was approved by U.S. FDA for treatment of giant-cell tumor of the tendon sheath (GC-TS). Pexidartinib is available in the US only through the Turalio Risk Evaluation and Mitigation Strategy (REMS) Program. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.